Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess safety, to measure blood levels of drug, and to find out what the drug does to the body.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: Single Ascending Dose (SAD) | Experimental | BMS-986171 or Placebo on specified days |
|
| Part B: Multiple Ascending Dose (MAD) | Experimental | BMS-986171 or Placebo on specified days |
|
| Part C: Multiple Ascending Dose in Japanese subjects (J-MAD) | Experimental | BMS-986171 or Placebo on specified days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986171 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of single dose of BMS-986171 will be measured by number of incidence of AEs, serious AEs, and events of special interest including injection site assessment, AEs leading to discontinuation | Adverse Event (AE) | up to 30 days after the last dose |
| Safety and tolerability of multiple subcutaneous doses of BMS-986171 will be measured by number of incidence of AEs, serious AEs, and events of special interest including injection site assessment, AEs leading to discontinuation | up to 30 days after the last dose | |
| Safety and tolerability of single dose of BMS-986171 will be measured by number of incidence of Death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, physical examinations | up to 30 days after the last dose | |
| Safety and tolerability of multiple subcutaneous doses of BMS-986171 will be measured by number of incidence of Death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, physical examinations | up to 30 days after the last dose |
| Measure | Description | Time Frame |
|---|---|---|
| Immunogenicity based on antibody responses | 6 months following study discharge. |
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Profil Institute For Clinical Research, Inc. | Chula Vista | California | 91911 | United States | ||
| Wcct Global, Llc |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Patient Recruiting | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other |
|
| Cypress |
| California |
| 90630 |
| United States |